GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:BIOVF) » Definitions » Earnings Yield (Joel Greenblatt) %

BIOVF (Swedish Orphan Biovitrum AB) Earnings Yield (Joel Greenblatt) % : 4.30% (As of Sep. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Swedish Orphan Biovitrum AB Earnings Yield (Joel Greenblatt) %?

Swedish Orphan Biovitrum AB's Enterprise Value for the quarter that ended in Sep. 2024 was $12,441 Mil. Swedish Orphan Biovitrum AB's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $541 Mil. Swedish Orphan Biovitrum AB's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2024 was 4.30%.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

BIOVF' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1.43   Med: 4.51   Max: 8.44
Current: 4.32

During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Swedish Orphan Biovitrum AB was 8.44%. The lowest was -1.43%. And the median was 4.51%.

BIOVF's Earnings Yield (Joel Greenblatt) % is ranked better than
60.92% of 1044 companies
in the Drug Manufacturers industry
Industry Median: 2.38 vs BIOVF: 4.32

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Swedish Orphan Biovitrum AB's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2024 was 6.46%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Swedish Orphan Biovitrum AB Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Earnings Yield (Joel Greenblatt) % Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.32 7.40 5.76 5.28 3.69

Swedish Orphan Biovitrum AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.51 3.69 3.55 3.60 4.30

Competitive Comparison of Swedish Orphan Biovitrum AB's Earnings Yield (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Earnings Yield (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Earnings Yield (Joel Greenblatt) % falls into.



Swedish Orphan Biovitrum AB Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Swedish Orphan Biovitrum ABs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=396.292/10827.54725
=3.66 %

Swedish Orphan Biovitrum AB's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $541 Mil.



Swedish Orphan Biovitrum AB  (OTCPK:BIOVF) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Swedish Orphan Biovitrum AB Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB Business Description

Traded in Other Exchanges
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).